Lubiprostone: Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 361-374

  Lunsford, Tisha N ^a   Harris, Lucinda A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Functional bowel disorder; Large intestine; Therapy

Indexed keywords

ION TRANSPORT AFFECTING AGENT; LINACLOTIDE; LUBIPROSTONE; PLACEBO; PRUCALOPRIDE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PREGNANT WOMAN; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 78650743393     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/IJWH.S4537     Document Type: Review

References (90)

1. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology. 2002;123(5):1686-1701.
2. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 SUPPL 1:S8-S35.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5): 1480-1491.
4. Drossman D, Li Z, Andruzzi E, et al. U.S, Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci. 1993;38(9):1569-1580.
5. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance, L. Functional gastrointestinal disorders in Canada: first population based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47(1):225-235.
6. Lee OY, Mayer EA, Schmulson, M, Chang, L, Naliboff B. Gender-related differences in IBS symptoms. Am J Gastroenterol. 2001;96(7):2184-2193.
7. Chang L, Toner BB, Fukodo S, et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130(5):1435-1446.
8. Chial HJ, Camilleri M. Gender differences in irritable bowel syndrome. J Gender Specif Med. 2002;5(3):37-45.
9. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. 1990;99(2):409-415.
10. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20 SUPPL 7:S31-S39.
11. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112(6):2120-2137.
12. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26(2):237-248.
13. Schiller LR, Dennis E, Toth G. Primary care physicians consider onstipation as a severe and bothersome medical condition that negatively impacts patients' lives [abstract 724]. Am J Gastroenterol. 2004;99 SUPPL:S234-S235.
14. Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol. 2004;38(9):776-781.
15. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007;41(4):345-351.
16. Lacy BE, Chey WD. Lubiprostone: chronic constipation and irritable bowel with constipation. Expert Opin Pharmacother. 2009;10(1):143-152.
17. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009;137(3):976-985.
18. Chang L, Lacy BE, Quigley EMM, Schoenfeld PS. Emerging diagnostic and treatment strategies for irritable bowel syndrome. Gastroenterol Hepatol. 2008;4(10):1-22.
19. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Healthrelated quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24(4):674-689.
20. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;27(8):685-696.
21. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006:23(1):191-196.
22. Lang, L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology. 2008;135(1):7.
23. Schiller LR, Camilleri M. Lubiprostone: viewpoints [comment]. Drugs. 2006;66(6):880-881.
24. ® (lubiprostone) [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc; 2009.
25. Orr, KK. Lubiprostone: a novel chloride channel activator for the treatment of constipation. Formulary. 2006;41(3):118-129.
26. Camilleri M, Bharucha A, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G942-G947.
27. Sweetser S, Busciglio IA, Camiller M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G295-G301.
28. Lipecka J, Bali M, Thomas J, et al. Distribution of CCl-2 chloride channel in rat and human epithelial tissue. Am J Physiol Cell Physiol. 2002;282(4):C805-C816.
29. Vandewalle A. Expression and function of CLC and cystic fibrosis transmembrane conductance regulator chloride channels in renal epithelial tubule cells pathophysiological implications. Chang Gung Med J. 2007;30(1):17-25.
30. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287(5):C1173-C1183.
31. Lubiprostone: RU 0211, SPI 0211. Drugs R D. 2005;6: 245-248.
32. Grider JR, Jin JG. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci. 1994;14 SUPPL 5(Pt 1):S2854-S2860.
33. Catalan M, Niemeyer MI, Cid LP, et al. Basolateral ClC-2 chloride hannels in surface colon epithelium: regulation by a direct effect of intracellular chloride. Gastroenterology. 2004;126(4):1104-1114.
34. Gyomorey K, Yeger H, Ackerly C. Expression of the chloride channel ClC-2 in the murine small intestine epithelium. Am J Physiol Cell Physiol. 2000;279(6):C1787-C1794.
35. Fritsch J, Edelman A. Modulation of the hyperpolarization-activated Cl- current in human T84 epithelial cells by phosphorylation. J Physiol. 1996;490(Pt 1):115-128.
36. Bao HF, Li L, Self J, et al. A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;295(2):G234-G251.
37. Tewari KP, Malinowska DH, Sherry AM, Cuppoletti J. PKA and arachidonic acid activation of human recombinant ClC-2 chloride channels. Am J Physiol Cell Physiol. 2000;279(1):C40-C50.
38. Fei G, Wang YZ, Liu S, et al. Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G823-G832.
39. Mizumori M, Akiba Y, Kaunitz JD. Lupiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci. 2009;54(10):2063-2069.
40. Bassil AK, Boman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol. 2008;154(1):126-135.
41. Cuppoletti J, Malinowsk DH, Chakrabarti J, Ueno R. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat. 2008;86(1-4):56-60.
42. Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterology. 2007;132(4 SUPPL2):A191-A192.
43. Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation on clinical electrocardiogram results. Gastroenterology. 2007;132(4 SUPPL 2):A325.
44. MacDonald KD, McKenzie KR, Henderson MJ, et al. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis Mice. Am J Physiol Lung Cell Mol Physiol. 2008;295(9):L933-L940.
45. Joo NS, Wine JJ, Cuthbert AW. Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs and humans. Am J Physiol Lung Cell Mol Physiol. 2009;296(5):L811-L824.
46. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the Regulation of G-protein levels in female chronic constipation. Gastroenterology. 2005;128(3):667-675.
47. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology. 1990;98(4):1187-1192.
48. Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology. 1997;112(1):55-63.
49. Ragnarrsson G, Hallbook O, Bodemar G. Abdominal symptoms are not related to anorectal function in the irritable bowel syndrome. Scand J Gastroenterol. 1999;34(3):250-258.
50. Chang L, Mayer EA, Labus J, et al. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol. 2006;29(2):R277-R284.
51. Houghton LA, Lea R, Jackson N, Whorwell PU. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut. 2002;50(4):471-474.
52. Berman S, Munakata J, Naliboff BD, et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain. 2000;4(2):157-172.
53. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients:central processing of visceral stimuli. Gastroenterology. 2003;124(7):1738-1747.
54. Camilleri, M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13(9): 1149-1159.
55. Chang L, Ameen VZ, Dukes GE, McSorley D, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron hydrochloride (Lotronex) in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100(1):115-123.
56. Bradette M, Moennikes H, Carter F, et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D). Efficacy and safety in a 6 month study. Gastroenterology. 2004; 126(4 SUPPL 2):A42.
57. Coremnans G, Clouse RE, Carter F, Krause, G, Caras S, Steinborm C. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea predominance (IBS-D). Gastroenterology. 2004;126(4 SUPPL 2):A643.
58. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5HT (4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15(10):1655-1666.
59. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, placebo controlled randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003;52(5):671-676.
60. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002;123(2):425-432.
61. Johanson JF, Gargano MA, Patchen ML, Ueno R. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation. Gastroenterology. 2002;122(1 SUPPL 4):A315.
62. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology. 2003;124(4 SUPPL 1):A48.
63. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III study of lubiprostone, a chloride channel-2 (CIC-2) activator for treatment of constipation: Safety and primary efficacy. Am J Gastroenterol. 2005; 100(9 SUPPL 9s):S328.
64. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channelc activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351-1361.
65. Barish CF, Drossman D, Johanson JF, Ueno R. Eff icacy and safety of lubiprostone in chronic constipation. Dig Dis Sci. 2010;55(4):1090-1097.
66. Johanson JF, Morton D, Geenen J, Ueno R. Multi-center, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170-177.
67. Thompson WG, Longstreth G, Drossman DA, Heaton K, Irvine EJ, Muller-Lissner S. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, editors. Rome II: The Functional Gastrointestinal Disorders. McLean VA: Dagnon Associates, Inc; 2000:351-432.
68. Anonymous. Lubiprostone (amitiza) for chronic constipation. Med Lett Drugs Ther. 2006;48(1236):47-48.
69. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology. 2003; 124(4 SUPPL 1):A104.
70. Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology. 2006; 130(4 SUPPL 2):A188.
71. Johanson JF, Gargano MA, Patchen ML, Ueno R. Multi-center open label study of lubiprostone for the treatment of chronic constipation. Am J Gastroenterol. 2005;100(9 SUPPL 9):S331.
72. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology. 2004; 126(4 SUPPL 2):S100
73. Chey WD, Saad RJ, Panas R, Wahle A, Ueno R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomized withdrawal study. Gastroenterology. 2008; 134(4 SUPPL 1):A401.
74. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341.
75. Drossman DA, Chey WD, Scott C, Panas R, Ueno R. Health-related quality of life in adults with irritable bowel syndrome with constipation: results of combined analysis of two phase 3 studies with lubiprostone. Gastroenterology. 2008;134(4 SUPPL 1):A469.
76. Chey WD, Drossman DA, Scott C, Panas R, Ueno R. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation: data from two multicenter, randomized, placebo-controlled trials. Gastroenterology. 2008;134(4 SUPPL 1):A28.
77. Camilleri M, Gorman H. Intestinal permeability and IBS. Neurogastroenterol Motil. 2007;19(7):545-552.
78. Dunlop SP, Hepben J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2006;101(6):1288-1204.
79. Marshall JK, Thabane M, Garg AX, Clark W, Medings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20(11-12):1317-1322.
80. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(5):804-811.
81. Crowell MD, Harris LA, Lunsford TN, DiBaise J. Emerging drugs for chronic constipation. Expert Opin Emerg Drugs. 2009;14(3): 493-504.
82. Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther. 2010;31(1):35-46.
83. Camilleri M, Kerstens R, Beyens G, Robinson P, Vandeplassche L. A double-blind, placebo controlled trial to evaluate the safety and tolerability of prucalo-pride oral solution in constipated elderly patients living in a nursing facility. Gastroenterology. 2009; 136 SUPPL 1:S240.
84. Camilleri M, Beyens G, Kertsens R, Vandeplassche L. Long-term follow up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation. Gastroenterology. 2009;136 SUPPL 1:S160.
85. Forte LR Jr. Uroguanylin and guanylin peptides: pharmacology and experimental and therapeutics. Pharmacol Ther. 2004;104(2):137-162.
86. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138(3):886-895.
87. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-550.
88. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. 1992;116(12 Pt 1):1009-1016.
89. Spiegel B, Harris LA, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF cohort. Am J Gastroenterol. 2009;104(8):1984-1991.
90. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol. 2008;103(10):2536-2543.